1155847-42-9Relevant articles and documents
NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS
-
Paragraph 00408, (2013/03/26)
The present invention provides compounds of Formula (Ia): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
Design and synthesis of pyridone inhibitors of non-nucleoside reverse transcriptase
Gomez, Robert,Jolly, Samson,Williams, Theresa,Tucker, Thomas,Tynebor, Robert,Vacca, Joe,McGaughey, Georgia,Lai, Ming-Tain,Felock, Peter,Munshi, Vandna,Destefano, Daniel,Touch, Sinoeun,Miller, Mike,Yan, Youwei,Sanchez, Rosa,Liang, Yuexia,Paton, Brenda,Wan, Bang-Lin,Anthony, Neville
scheme or table, p. 7344 - 7350 (2012/02/04)
Next generation NNRTIs are sought which possess both broad spectrum antiviral activity against key mutant strains and a high genetic barrier to the selection of new mutant viral strains. Pyridones were evaluated as an acyclic conformational constraint to
NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS
-
Page/Page column 114-115, (2009/06/27)
Heteroaromatic compounds of Formula (I), are HIV reverse transcriptase inhibitors, wherein ring A is: (ii-a), (ii-b), (ii-c), (ii-d), or (ii-e); and wherein n, L, M, U, X, Y, Z, RE, RF, R1, R2A, R2B,